Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS To determine the cost-effectiveness of anti-obesity medications (AOM): tirzepatide, semaglutide, liraglutide, phentermine plus topiramate (PpT), and naltrexone plus bupropion (NpB). METHODS AND RESULTS From a U.S. perspective we developed a Markov model to simulate weight change over a 40-year time horizon using results from clinical studies. According to the body mass index (BMI), cardiovascular diseases, diabetes and mortality risk were the health states considered in the model, being mutually exclusive. Costs of AOM, adverse events, cardiovascular events, and diabetes were included. We applied a 3% per-year discount rate and calculated the incremental cost-effectiveness ratios (ICERs) of cost per quality-adjusted life-year (QALY) gained. Probabilistic sensitivity analyses incorporated uncertainty in input parameters. A deterministic analysis was conducted to determine the robustness of the model. The model included a cohort of 78.2% females with a mean age of 45 years and BMI of 37.1 (SD 4.9) for females and 36.8 (SD 4.9) for males. NpB and PpT were the least costly medications and, all medications differed no more than 0.5 QALYs. Tirzepatide ICER was $355,616 per QALY. Liraglutide and semaglutide options were dominated by PpT. CONCLUSION Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
Ward, Z. J., Bleich, S. N., Cradock, A. L., Barrett, J. L., Giles, C. M., Flax, C., Long, M. W., & Gortmaker, S. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmsa1909301 · Cited by 2,009
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Direct medical costs of obesity in the United States and the most populous states
Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400
Tomiyama, A. J., Hunger, J. M., Nguyen-Cuu, J., & Wells, C. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.17 · Cited by 349
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity · doi:10.1002/oby.22054 · Cited by 312
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200
The costs of adverse drug events in community hospitals
Hug, B. L., Keohane, C., Seger, D. L., Yoon, C., & Bates, D. W. (2012) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(12)38016-1 · Cited by 169
Gomez, G., & Stanford, F. C. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.287 · Cited by 128
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.7.740 · Cited by 81
Jannah, N., Hild, J., Gallagher, C., & Dietz, W. (2018) · Obesity · doi:10.1002/oby.22307 · Cited by 72
The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020) · Obesity Science & Practice · doi:10.1002/osp4.390 · Cited by 61
Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes
Gazda, C. L., Clark, J. D., Lingvay, I., & Almandoz, J. P. (2021) · Obesity · doi:10.1002/oby.23146 · Cited by 56
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45
Claridy, M. D., Czepiel, K. S., Bajaj, S. S., & Stanford, F. C. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.07.021 · Cited by 37
Cited by
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29178 · Cited by 42
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Mital, S., & Nguyen, H. V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36400 · Cited by 41
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
Metadata
- Authors
- Gómez Lumbreras, A., Tan, M. S., Villa-Zapata, L., Ilham, S., Earl, J. C., & Malone, D. C.
- Venue
- Nutrition, Metabolism and Cardiovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 33
- Issue
- 6
- Pages
- 1268-1276
- ISSN
- 0939-4753 (ISSN-L)
- OpenAlex
- W4360943385
- Cited by
- 34
- References
- 32
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.